{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:05:43Z","timestamp":1791331543117,"version":"4.3.1"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Amphotericin B (AMB) remains the principal therapeutic choice for deep mycoses. However, its application is limited by toxicity and a route of administration requiring slow intravenous injection. An oral formulation of this drug is desirable to treat acute infections and provide prophylactic therapy for high-risk patients. Cochleates are a novel lipid-based delivery system that have the potential for oral administration of hydrophobic drugs. They are stable phospholipid-cation crystalline structures consisting of a spiral lipid bilayer sheet with no internal aqueous space. Cochleates containing AMB (CAMB) inhibit the growth of\n            <jats:italic>Candida albicans<\/jats:italic>\n            , and the in vivo therapeutic efficacy of CAMB administered orally was evaluated in a mouse model of systemic candidiasis. The results indicate that 100% of the mice treated at all CAMB doses, including a low dosage of 0.5 mg\/kg of body weight\/day, survived the experimental period (16 days). In contrast, 100% mortality was observed with untreated mice by day 12. The fungal tissue burden in kidneys and lungs was assessed in parallel, and a dose-dependent reduction in\n            <jats:italic>C. albicans<\/jats:italic>\n            from the kidneys was observed, with a maximum 3.5-log reduction in total cell counts at 2.5 mg\/kg\/day. However, complete clearance of the organism from the lungs, resulting in more than a 4-log reduction, was observed at the same dose. These results were comparable to a deoxycholate AMB formulation administered intraperitoneally at 2 mg\/kg\/day (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). Overall, these data demonstrate that cochleates are an effective oral delivery system for AMB in a model of systemic candidiasis.\n          <\/jats:p>","DOI":"10.1128\/aac.44.9.2356-2360.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"2356-2360","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":132,"title":["Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis"],"prefix":"10.1128","volume":"44","author":[{"given":"Rosaria","family":"Santangelo","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Public Health Research Institute, New York, New York, 10016,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja","family":"Paderu","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Public Health Research Institute, New York, New York, 10016,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Delmas","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Public Health Research Institute, New York, New York, 10016,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->BioDelivery Science Inc. UMDNJ, Newark, New Jersey 071032"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mannino","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->BioDelivery Science Inc. UMDNJ, Newark, New Jersey 071032"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Zarif","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->BioDelivery Science Inc. UMDNJ, Newark, New Jersey 071032"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Perlin","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Public Health Research Institute, New York, New York, 10016,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"S3","article-title":"AmBisome targeting to fungal infections.","volume":"14","author":"Adler-Moore J.","year":"1994","unstructured":"Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14 (Suppl. 5) 1994 S3 S7","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150729"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/28.suppl_B.63","article-title":"Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome).","volume":"28","author":"Adler-Moore J. P.","year":"1991","unstructured":"Adler-Moore J. P. Chiang S. M. Satorius A. Guerra D. McAndrews B. McManus E. J. Proffitt R. T. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28 (Suppl. B) 1991 63 71","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0002-9343(98)00030-8","article-title":"Predictors of adverse outcome in cancer patients with candidemia.","volume":"104","author":"Anaissie E. J.","year":"1998","unstructured":"Anaissie E. J. Rex J. H. Uzun O. Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. 104 1998 238 245","journal-title":"Am. J. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/clinids\/16.1.1","article-title":"Treatment of opportunistic fungal infections.","volume":"16","author":"Armstrong D.","year":"1993","unstructured":"Armstrong D. Treatment of opportunistic fungal infections. Clin. Infect. Dis. 16 1993 1 7","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21548331.1992.11705537","article-title":"Liposomes: realizing their promise.","volume":"27","author":"Bangham A. D.","year":"1992","unstructured":"Bangham A. D. Liposomes: realizing their promise. Hosp. Pract. 27 1992 51 56","journal-title":"Hosp. Pract."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/infdis\/167.5.1247","article-title":"Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980\u20131990. National Nosocomial Infections Surveillance System.","volume":"167","author":"Beck-Sague C.","year":"1993","unstructured":"Beck-Sague C. Jarvis W. R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980\u20131990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167 1993 1247 1251","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/1097-0142(19940415)73:8<2099::AID-CNCR2820730814>3.0.CO;2-N","article-title":"Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.","volume":"73","author":"Bodey G. P.","year":"1994","unstructured":"Bodey G. P. Anaissie E. J. Elting L. S. Estey E. O'Brien S. Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73 1994 2099 2106","journal-title":"Cancer"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.2.300"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.2.183"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2125.1983.tb02152.x","article-title":"Absorption of orally administered amphotericin B lozenges.","volume":"16","author":"Ching M. S.","year":"1983","unstructured":"Ching M. S. Raymond K. Bury R. W. Mashford M. L. Morgan D. J. Absorption of orally administered amphotericin B lozenges. Br. J. Clin. Pharmacol. 16 1983 106 108","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.3.362"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0924-977X(92)90025-4","article-title":"Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type.","volume":"2","author":"Engel R. R.","year":"1992","unstructured":"Engel R. R. Satzger W. Gunther W. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Neuropsychopharmacology 2 1992 149 155","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/clind\/15.3.414","article-title":"Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.","volume":"15","author":"Fraser V. J.","year":"1992","unstructured":"Fraser V. J. Jones M. Dunkel J. Storfer S. Medoff G. Dunagan W. C. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15 1992 414 421","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1093\/clinids\/22.Supplement_2.S145","article-title":"Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials.","volume":"22","author":"Gallis H. A.","year":"1996","unstructured":"Gallis H. A. Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin. Infect. Dis. 22 (Suppl. 2) 1996 S145 S147","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/infdis\/164.4.731","article-title":"Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation.","volume":"164","author":"Goodrich J. M.","year":"1991","unstructured":"Goodrich J. M. Reed E. C. Mori M. Fisher L. D. Skerrett S. Dandliker P. S. Klis B. Counts G. W. Meyers J. D. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J. Infect. Dis. 164 1991 731 740","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-2008-1043890","article-title":"Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.","volume":"210","author":"Groll A. H.","year":"1998","unstructured":"Groll A. H. Muller F. M. Piscitelli S. C. Walsh T. J. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin. Paediatr. 210 1998 264 273","journal-title":"Klin. Paediatr."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/02652049809006844","article-title":"Development of liposomal amphotericin B formulation.","volume":"15","author":"Gulati M.","year":"1998","unstructured":"Gulati M. Bajad S. Singh S. Ferdous A. J. Singh M. Development of liposomal amphotericin B formulation. J. Microencapsul. 15 1998 137 151","journal-title":"J. Microencapsul."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-4453(94)95956-0","article-title":"Liposomal amphotericin B, AmBisome.","volume":"28","author":"Hay R. J.","year":"1994","unstructured":"Hay R. J. Liposomal amphotericin B, AmBisome. J. Infect. 28 (Suppl. 1) 1994 35 43","journal-title":"J. Infect."},{"key":"e_1_3_2_22_2","first-page":"S8","article-title":"Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.","volume":"14","author":"Heinemann V.","year":"1994","unstructured":"Heinemann V. Kahny B. Debus A. Wachholz K. Jehn U. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant. 14 (Suppl. 5) 1994 S8 S9","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions.","volume":"22","author":"Hiemenz J. W.","year":"1996","unstructured":"Hiemenz J. W. Walsh T. J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22 (Suppl. 2) 1996 S133 S144","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_24_2","first-page":"130","article-title":"Antibiotic-related nephrotoxicity.","volume":"9","author":"Kaloyanides G. J.","year":"1994","unstructured":"Kaloyanides G. J. Antibiotic-related nephrotoxicity. Nephrol. Dial. Transplant. 9 (Suppl. 4) 1994 130 134","journal-title":"Nephrol. Dial. Transplant."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/313583","article-title":"Prospective multicenter surveillance study of funguria in hospitalized patients.","volume":"30","author":"Kauffman C. A.","year":"2000","unstructured":"Kauffman C. A. Vazquez J. A. Sobel J. D. Gallis H. A. McKinsey D. S. Karchmer A. W. Sugar A. M. Sharkey P. K. Wise G. J. Mangi R. Mosher A. Lee J. Y. Dismukes W. E. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin. Infect. Dis. 30 2000 14 18","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00944.x"},{"key":"e_1_3_2_27_2","unstructured":"Mannino\n              R. J.\n              Gould-Fogerite\n              S.\n          Antigen cochleate formulations for oral and systemic vaccination in new generation vaccines\n          New generation vaccines.\n              Levine\n              M. M.\n          1997\n          1\n          9\n          Marcel Dekker\n          New York N.Y"},{"key":"e_1_3_2_28_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard NCCLS document M27-A.\n          1997\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(95)00010-0"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00000658-199601000-00010","article-title":"Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients.","volume":"223","author":"Nieto-Rodriguez J. A.","year":"1996","unstructured":"Nieto-Rodriguez J. A. Kusne S. Manez R. Irish W. Linden P. Magnone M. Wing E. J. Fung J. J. Starzl T. E. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann. Surg. 223 1996 70 76","journal-title":"Ann. Surg."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0005-2736(75)90299-0","article-title":"Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles.","volume":"394","author":"Papahadjopoulos D.","year":"1975","unstructured":"Papahadjopoulos D. Vail W. J. Jacobson K. Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta 394 1975 483 491","journal-title":"Biochim. Biophys. Acta"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.7.1886-1889.1998"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0732-8893(97)00240-X","article-title":"National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.","volume":"31","author":"Pfaller M. A.","year":"1998","unstructured":"Pfaller M. A. Jones R. N. Messer S. A. Edmond M. B. Wenzel R. P. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 31 1998 327 332","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2710.1999.00220.x","article-title":"A comparative review of conventional and lipid formulations of amphotericin B.","volume":"24","author":"Robinson R. F.","year":"1999","unstructured":"Robinson R. F. Nahata M. C. A comparative review of conventional and lipid formulations of amphotericin B. J. Clin. Pharm. Ther. 24 1999 249 257","journal-title":"J. Clin. Pharm. Ther."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005020-00003"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1681\/ASN.V62154","article-title":"Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.","volume":"6","author":"Sawaya B. P.","year":"1995","unstructured":"Sawaya B. P. Briggs J. P. Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. 6 1995 154 164","journal-title":"J. Am. Soc. Nephrol."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/sj.bmt.1701829","article-title":"Safety of high-dose amphotericin B lipid complex.","volume":"24","author":"Singhal S.","year":"1999","unstructured":"Singhal S. Hastings J. G. Mutimer D. J. Safety of high-dose amphotericin B lipid complex. Bone Marrow Transplant. 24 1999 116 177","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_2_38_2","first-page":"84","article-title":"Multicenter clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration.","volume":"24","author":"Villardita C.","year":"1987","unstructured":"Villardita C. Grioli S. Salmeri G. Nicoletti F. Pennisi G. Multicenter clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin. Trials J. 24 1987 84 93","journal-title":"Clin. Trials J."},{"key":"e_1_3_2_39_2","first-page":"187","article-title":"Invasive fungal infections in children: recent advances in diagnosis and treatment.","volume":"11","author":"Walsh T. J.","year":"1996","unstructured":"Walsh T. J. Gonzalez C. Lyman C. A. Chanock S. J. Pizzo P. A. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. 11 1996 187 290","journal-title":"Adv. Pediatr. Infect. Dis."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2391"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/28.suppl_B.27","article-title":"Amphotericin B: an introduction.","volume":"28","author":"Warnock D. W.","year":"1991","unstructured":"Warnock D. W. Amphotericin B: an introduction. J. Antimicrob. Chemother. 28 (Suppl. B) 1991 27 38","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities.","volume":"27","author":"Wong-Beringer A.","year":"1998","unstructured":"Wong-Beringer A. Jacobs R. A. Guglielmo B. J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27 1998 603 618","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0891-5520(05)70363-9","article-title":"Nosocomial Candida. Epidemiology, transmission, and prevention.","volume":"11","author":"Wright W. L.","year":"1997","unstructured":"Wright W. L. Wenzel R. P. Nosocomial Candida. Epidemiology, transmission, and prevention. Infect. Dis. Clin. N. Am. 11 1997 411 425","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","unstructured":"Zarif\n              L.\n              Mannino\n              R. J.\n          Cochleates: lipid-based vehicles for gene delivery\u2014concept achievements and future development\n          Cancer gene therapy: past achievements and future challenges.\n              Habib\n              N.\n          2000\n          83\n          94\n          Plenum Publishing Co.\n          London England","DOI":"10.1007\/0-306-46817-4_9"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1463-1469.2000"},{"key":"e_1_3_2_47_2","first-page":"S-453","article-title":"Oral and systemic delivery of AmB mediated by cochleates.","volume":"1","author":"Zarif L.","year":"1999","unstructured":"Zarif L. Segarra L. Jin T. Scolpino A. Hyra D. Perlin D. S. Graybill J. R. Mannino R. J. Oral and systemic delivery of AmB mediated by cochleates. AAPS PharmSci. 1 1999 S-453","journal-title":"AAPS PharmSci."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.9.2356-2360.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.9.2356-2360.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:42:23Z","timestamp":1645461743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.9.2356-2360.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1128\/AAC.44.9.2356-2360.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.9.2356-2360.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]},"assertion":[{"value":"2000-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-06-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}